Arcturus Corp (ARCT) Cash per Single Share

Arcturus Corp - graphic logo of issuer ARCT

The growth of Arcturus Therapeutics (ARCT) is driven by the success of mRNA vaccines in Japan and a debt-free balance sheet. The cash per share trend demonstrates financial stability, where the value 6.42 represents the current liquidity metric. Efficiency is maintained by outsourcing trials to external contractors and attracting top scientists through a stock option system, ensuring the development of innovative therapies for rare diseases.

Arcturus Therapeutics Holdings Inc. (ARCT): Cash per Share from 07/04/2022 to 11/20/2026

Comprehensive metric breakdowns and analytics for Arcturus Therapeutics Inc (ARCT)

- cash availability and cash flow indicators:
General company analysis:Arcturus Therapeutics, ARCT
Flagship merchandise of Arcturus Therapeutics Holdings Inc.

For Arcturus Therapeutics (ARCT), amid the fierce battle for RNA patents against biotech behemoths, this metric serves as an indicator of financial autonomy and protection against takeovers. By analyzing the trend of liquid assets per share, an investor assesses the volume of the actual cash balance divided by the number of shares, which determines the company's ability to fund research and development without attracting expensive external capital.